Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. <\/p>\n
Kyle Grillot | Bloomberg | Getty Images<\/p>\n
Johnson & Johnson<\/a> said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate to severe atopic dermatitis after it failed to meet efficacy goals in an interim analysis.<\/p>\n The drug, JNJ-5939, was being tested in patients with atopic dermatitis, or eczema, a skin condition that causes inflammation, redness and intense itching.<\/p>\n The drug was well-tolerated but did not meet the “high-bar” efficacy required to advance development, the company said.<\/p>\n Johnson & Johnson said it remains committed to developing treatments for atopic dermatitis, a chronic condition that affects more than 100 million people worldwide.<\/p>\n The company is developing other experimental treatments for atopic dermatitis, including bispecific antibodies NM26, PX128 and PX130, as well as an oral STAT6 inhibitor, KP\u2011723.<\/p>\n Eczema has multiple approved treatments, such as Sanofi<\/a> and Regeneron’s<\/a> Dupixent, AbbVie’s<\/a> Rinvoq, Pfizer’s<\/a> Cibinqo, Eli Lilly’s<\/a> Ebglyss, as well as some generic drugs such as cetirizine.<\/p>\n","protected":false},"excerpt":{"rendered":"Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg |…\n","protected":false},"author":2,"featured_media":252470,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[275],"tags":[88079,11589,207,18,479,135,475,11588,474,19,17,2994,57562,131103,131102],"class_list":{"0":"post-252469","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-abbvie-inc","9":"tag-biotech-and-pharmaceuticals","10":"tag-business-news","11":"tag-eire","12":"tag-eli-lilly-and-co","13":"tag-health","14":"tag-health-care","15":"tag-health-care-industry","16":"tag-healthcare","17":"tag-ie","18":"tag-ireland","19":"tag-johnson-johnson","20":"tag-pfizer-inc","21":"tag-regeneron-pharmaceuticals-inc","22":"tag-sanofi-sa"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/115786403197434043","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/252469","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=252469"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/252469\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/252470"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=252469"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=252469"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=252469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}